Boston Scientific seeks to consistently meet or exceed our financial commitments. Our goal is to continue delivering on our long term, mid-single digit revenue growth, continued adjusted operating margin expansion and double-digit adjusted EPS growth.
A Track-Record of Driving Adjusted Operating Margin1 Expansion
Across Boston Scientific, our teams are focused on improving productivity and reducing costs so that we can redirect savings into high-growth technologies, strategic investments and our future portfolio. We have a proven track record of driving operating margin expansion since 2012 and achieved our goal of a 25 percent adjusted operating margin by 2017.
We are committed to sustained expansion, with a longer term goal to grow our adjusted operating margin to 30+ percent. Key contributors include enhanced SG&A productivity, key product launches and commercial scale of acquisitions, standard cost improvements, ongoing manufacturing site optimization, and R&D efficiencies.
Generating Strong Cash Flow
We’re committed to generating strong adjusted free cash flow1 and target approximately 10 percent growth from 2019 to 2022, with improved ability to deploy for strategic purposes.
1 Non-GAAP measure; excludes certain GAAP items. For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to our Financial Disclaimers and Non-GAAP Reconciliations.